| Literature DB >> 33794836 |
Suochen Tian1, Min Wu2, Zhenqin Chang3, Yunxia Wang4, Guijie Zhou4, Wenming Zhang4, Junmin Xing5, Hui Tian5, Xihong Zhang5, Xiuli Zou5, Lina Zhang5, Mingxin Liu6, Juan Chen7, Jian Han8, Kang Ning9, Shuangfeng Chen10, Tiejun Wu11.
Abstract
BACKGROUND: In view of the ongoing coronavirus disease (COVID-19) pandemic, it remains unclear whether the severity of illness and time interval from symptom onset to release from quarantine differ between cases that originated from clusters and cases reported in other areas. This study aimed to assess epidemiological and intergenerational clinical characteristics of COVID-19 patients associated with cluster outbreaks to provide valuable data for the prevention and control of COVID-19.Entities:
Keywords: COVID-19; Clinical characteristics; Cluster; Epidemiology; Generation
Mesh:
Year: 2021 PMID: 33794836 PMCID: PMC8016429 DOI: 10.1186/s12889-021-10713-z
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Fig. 1Time distribution of confirmed symptomatic coronavirus disease (COVID-19) patients associated with a supermarket cluster
Fig. 2Transmission chain and intergenerational relationship
Fig. 3Computed tomography findings of 7 asymptomatic coronavirus disease (COVID-19) patients on admission
Clinical characteristics of the study patients on admission
| Characteristics | All patients | Group | ||
|---|---|---|---|---|
| A | B | |||
| Age (y) | 48 ± 1.73 | 42.05 ± 9.46 | 53 ± 2.09 | 0.11 |
| Gender | ||||
| Male (%) | 9/24 (37.50) | 1/11 (9.09) | 8/13 (61.54) | 0.013 |
| Female (%) | 15/24 (62.50) | 10/11 (90.91) | 5/13 (38.46) | |
| Duration from onset to hospitalization (d) | 5.5 (7) | 3 (5) | 6 (4) | 0.011 |
| PSI | 0 (57.25) | 0 (44) | 45 (72.5) | 0.252 |
| I (%) | 16/24 (66.67) | 9/11 (81.82) | 7/13 (53.85) | |
| II ≤70 (%) | 4/24 (16.67) | 1/11 (9.09) | 3/13 (23.08) | |
| III 71–90 (%) | 3/24 (12.50) | 1/11 (9.09) | 2/13 (15.38) | |
| IV 91–131 (%) | 1/24 (4.17) | 0/11 (0) | 1/13 (7.69) | |
| V > 130 (%) | 0/37 (0) | 0/19 (0) | 0/18 (0) | |
| Underlying disease | ||||
| Any (%) | 6/24 (25.00) | 0/11 (0) | 6/13 (46.15) | 0.016 |
| Hypertension (%) | 2/24 (8.33) | 0/11 (0) | 2/13 (15.38) | 0.482 |
| Coronary heart disease (%) | 2/24 (8.33) | 0/11 (0) | 2/13 (15.38) | 0.482 |
| Diabetes (%) | 1/24 (4.17) | 0/11 (0) | 1/13 (7.69) | 1 |
| Cirrhosis, liver cancer (%) | 1/24 (4.17) | 0/11 (0) | 1/13 (7.69) | 1 |
| Symptoms | ||||
| Asymptomatic (%) | 7/24 (29.17) | 6/11 (54.55) | 1/13 (7.69) | 0.023 |
| Fever (%) | 15/24 (62.50) | 5/11 (45.45) | 10/13 (76.92) | 0.206 |
| Fatigue (%) | 5/24 (20.83) | 1/11 (9.09) | 4/13 (30.77) | 0.327 |
| Headache (%) | 1/24 (4.17) | 1/11 (9.09) | 0/13 (0) | 0.458 |
| Nasal congestion (%) | 2/24 (8.33) | 0/11 (0) | 2/13 (15.38) | 0.482 |
| Sore throat (%) | 6/24 (25.00) | 2/11 (18.18) | 4/13 (30.77) | 0.649 |
| Cough (%) | 17/24 (70.83) | 8/11 (72.73) | 9/13 (69.23) | 1 |
| Hemoptysis (%) | 1/24 (4.17) | 0/11 (0) | 1/13 (7.69) | 1 |
| Shortness of breath (%) | 10/24 (41.67) | 3/11 (27.27) | 7/13 (53.85) | 0.240 |
| Vomiting or diarrhea (%) | 6/24 (25.00) | 3/11 (27.27) | 3/13 (23.08) | 1 |
| Pain in a muscle or joint (%) | 1/24 (4.17) | 0/11 (0) | 1/13 (7.69) | 1 |
| Laboratory findings | ||||
| WBC < 4.0 × 109/L (%) | 7/24 (29.17) | 3/11 (27.27) | 4/13 (30.77) | 1 |
| L < 1.1 × 109/L (%) | 14/24 (58.33) | 6/11 (54.55) | 8/13 (61.54) | 1 |
| L ≤ 0.6 × 109/L (%) | 7/14 (50.00) | 3/6 (50.0) | 4/8 (50.00) | 1 |
| SAA > 10 mg/L (%) | 15/24 (62.50) | 5/11 (45.45) | 10/13 (76.92) | 0.206 |
| CRP > 5 mg/L (%) | 12/24 (50.00) | 3/11 (27.27) | 9/13 (69.23) | 0.1 |
| PCT > 0.5 ng/ml (%) | 2/24 (8.33) | 2/11 (18.18) | 0/13 (0) | 0.199 |
| LDH > 250 U/L (%) | 5/24 (20.83) | 1/11 (9.09) | 4/13 (30.77) | 0.327 |
| Alb < 40 g/L (%) | 17/24 (70.83) | 8/11 (72.73) | 9/13 (69.23) | 1 |
| AST > 40 U/L (%) | 2/24 (8.33) | 1/11 (9.09) | 1/13 (7.69) | 1 |
| ALT > 40 U/L (%) | 1/24 (4.17) | 1/11 (9.09) | 0/13 (0) | 0.458 |
| TBL > 17.1 mmol/L (%) | 9/24 (37.50) | 3/11 (27.27) | 6/13 (46.15) | 0.423 |
| D-dimer > 0.5 mg/L (%) | 6/24 (25.00) | 3/11 (27.27) | 3/13 (23.08) | 1 |
| Fib > 4 g/L (%) | 6/24 (25.00) | 3/11 (27.27) | 3/13 (23.08) | 1 |
| ESR ≥20 mm/h (%) | 18/24 (75.00) | 8/11 (72.73) | 10/13 (76.92) | 1 |
| Chest CT findings | ||||
| Pneumonia (%) | 24/24 (100) | 11/11 (100) | 13/13 (100) | – |
| Bilateral infiltration (%) | 18/24 (75.00) | 7/11 (63.64) | 11/13 (84.62) | 0.357 |
| Unilateral infiltration (%) | 6/24 (25.00) | 4/11 (36.36) | 2/13 (15.38) | |
Disease severity classification among patients and complications and treatment measures before release from quarantine
| Characteristics | All patients | Group | ||
|---|---|---|---|---|
| A | B | |||
| Disease severity | 0.776 | |||
| Mild (%) | 0/24 (0) | 0/11 (0) | 0/13 (0) | |
| Moderate (%) | 23/24 (95.83) | 11/11 (100) | 12/13 (92.31) | |
| Severe (%) | 1/24 (4.17) | 0/11 (0) | 1/13 (7.69) | |
| Critical (%) | 0/24 (0) | 0/11 (0) | 0/13 (0) | |
| Complications | ||||
| ARDS (%) | 1/24 (4.17) | 0/11 (0) | 1/13 (7.69) | 1 |
| Treatment | ||||
| Antibiotics | 17/24 (70.83) | 9/11 (81.82) | 8/13 (61.54) | 0.386 |
| Antifungal drugs | 1/24 (4.17) | 0/11 (0) | 1/13 (7.69) | 1 |
| Antiviral drugs (%) | 24/24 (100) | 11/11 (100) | 13/13 (100) | – |
| Glucocorticoids (%) | 5/24 (20.83) | 2/11 (18.18) | 3/13 (23.08) | 1 |
| Albumin (%) | 11/24 (45.83) | 2/11 (18.18) | 9/13 (69.23) | 0.019 |
| Immunoglobulin (%) | 6/24 (25.00) | 2/11 (18.18) | 4/13 (30.77) | 0.649 |
| Thymosin (%) | 15/24 (62.50) | 7/11 (63.64) | 8/13 (61.54) | 1 |
| Oxygen therapy (%) | 11/24 (45.83) | 4/11 (36.36) | 7/13 (53.85) | 0.444 |
| Common (%) | 10/11 (90.91) | 4/4 (100) | 6/7 (85.71) | 1 |
| HFNC (%) | 1/11 (9.09) | 0/4 (0) | 1/7 (14.29) | |
| TCM (%) | 24/24 (100) | 11/11 (100) | 13/13 (100) | – |
Clinical outcomes of patients
| Outcomes | All patients | Group | ||
|---|---|---|---|---|
| A | B | |||
| Hospitalization duration (d) | 16 ± 6.15 | 16 ± 6.66 | 16 ± 5.96 | 1 |
| Duration from onset to release from quarantine (d) | 21.04 ± 6.77 | 19.09 ± 7.92 | 22.69 ± 5.41 | 0.201 |
| Blood findings at the time of release from quarantine | ||||
| WBC < 4.0 × 109/L (%) | 3/24 (12.50) | 1/11 (9.09) | 2/13 (15.38) | 1 |
| L < 1.1 × 109/L (%) | 14/24 (58.33) | 7/11 (63.64) | 7/13 (53.85) | 0.697 |
| L ≤ 0.6 × 109/L (%) | 4/14 (28.57) | 1/7 (14.29) | 3/7 (42.86) | 0.559 |
| SAA > 10 mg/L (%) | 4/24 (16.67) | 1/11 (9.09) | 3/13 (23.08) | 0.596 |